Ultragenyx Pharmaceutical (RARE) : The consensus price target for Ultragenyx Pharmaceutical (RARE) is $93.58 for the short term with a standard deviation of $14. The most optimist securities analyst among the 12 who monitor the stock believes that the stock can reach $125, however, the pessimist price target for the company is $74.
Ultragenyx Pharmaceutical (RARE) : 11 brokerage houses believe that Ultragenyx Pharmaceutical (RARE) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Ultragenyx Pharmaceutical (RARE). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 13 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.23.
Also, Piper Jaffray initiates coverage on Ultragenyx Pharmaceutical (NASDAQ:RARE) The brokerage firm has issued a Overweight rating on the shares. The Analysts at the ratings agency announces the price target to $70 per share. The rating by the firm was issued on July 7, 2016.
Ultragenyx Pharmaceutical (NASDAQ:RARE): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $66.26 and $64.99 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $66.72. The buying momentum continued till the end and the stock did not give up its gains. It closed at $66.28, notching a gain of 0.54% for the day. The total traded volume was 280,763 . The stock had closed at $65.92 on the previous day.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).